leadf
logo-loader
viewAequus Pharmaceuticals Inc.

Aequus announces Anne Stevens is stepping down as chief operating officer

Stevens will remain a director and continue to serve on the board

Aequus Pharmaceuticals Inc. - Aequus Pharmaceuticals Inc says Anne Stevens is stepping down as chief operating officer
Aequus and partner Medicom Healthcare have been issued a new Medical Device License for the first of three product submissions for the Evolve preservative-free dry eye product line

Aequus Pharmaceuticals Inc. (CVE:AQS) (OTCQB:AQSZF) (FRA:AEQ), a specialty pharmaceutical company, announced Friday that Anne Stevens is stepping down as chief operating officer. 

Stevens will remain a director and continue to serve on the board, the Vancouver-based company said in a statement. 

“Anne and I co-founded Aequus together and I want to thank her for her many contributions over the years,” said CEO Doug Janzen. “Anne is an incredibly talented and effective executive who is leaving the company in excellent shape and well-positioned for success in the years to come. We are excited about her future plans and look forward to her continued work with the Aequus Board.”

READ: Aequus and partner Medicom Healthcare win Medical Device License for Evolve Intensive Gel to treat Dry Eye Disease

Stevens added: “It is extraordinary to see how Aequus has grown to be the mature commercial entity it is today, with a sharp focus and great momentum towards being a meaningful contributor to the Eye Care landscape in Canada. I believe that the commercial team is well prepared for my departure under the leadership of Grant Larsen and I look forward to watching a strong launch of the Evolve line of eye care products in Canada.”

Aequus and its partner Medicom Healthcare Ltd have been issued a new Medical Device License for the first of three product submissions for the Evolve preservative-free dry eye product line. 

The Evolve Intensive Gel – a unique cross-linked combination of Carbomer 980, Hyaluronate and glycerol – provides intensive, durable hydration for patients with moderate to severe forms of Dry Eye Disease. The formulation will be made available in an easy-squeeze eye drop bottle containing 360 drops, and no preservatives, phosphates, or buffers. 

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.225 CAD

TSX-V:AQS
Market: TSX-V
Market Cap: $25.18 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Aequus Pharmaceuticals receives approval for Evolve Gel lubricating eye...

Aequus Pharmaceuticals (CVE: AQS- OTCQB: AQSZF) CEO Doug Janzen joined Steve Darling from Proactive Vancouver with news the company has been granted a medical device licence for Evolve Intensive Gel. This product is a preservative free treatment for moderate to severe forms of dry-eye...

on 10/19/2020

2 min read